Latest Research Highlights

Basic Mobic Information

• INN (International Nonproprietary Name): Meloxicam.
• Brand Names Available In Australia: Mobic and generic meloxicam products are available; Mobic has historically been the innovator brand with generics now common.
• ATC Code: M01AC06.
• Forms & Dosages: Oral tablets 7.5 mg and 15 mg; oral suspension 7.5 mg/5 mL; capsules reported in some markets; IV solution 30 mg/1 mL single-use vials.
• Manufacturers In Australia: Original developer Boehringer Ingelheim is noted worldwide; local supply typically includes multiple generic suppliers.
• Registration Status In Australia: Listed as a prescription medicine in Australia.
• OTC / Rx Classification: Prescription-only (Rx) in major markets, including Australia.

Worried whether recent studies change how meloxicam is used in Australia?

Recent trials from 2022–2025 continued to support meloxicam as a long‑acting oxicam NSAID with reliable analgesic effect for osteoarthritis and inflammatory arthropathies compared with placebo and some NSAID comparators.

International randomised trials of a single 30 mg IV dose showed non‑inferior control of acute postoperative pain and, in some groups, a faster onset than oral meloxicam.

Australian registry and hospital pharmacovigilance up to 2024 report similar gastrointestinal and cardiovascular safety profiles to other non‑selective NSAIDs when used long term.

Surveillance also highlights higher absolute risk in Indigenous and remote communities due to baseline comorbidity and polypharmacy.

TGA reports from 2022–24 recorded hepatic enzyme rises and rare serious skin reactions, while renal adverse events tended to cluster in elderly patients with pre‑existing impairment.

Key pharmacology points include a plasma half‑life of approximately 20 hours and common formulations of 7.5 mg and 15 mg tablets, 7.5 mg/5 mL suspension and IV 30 mg.

Useful search terms patients use include meloxicam safety, meloxicam studies Australia and IV meloxicam.

Clinical Effectiveness In Australia

Wondering how clinicians in Australia actually use meloxicam for arthritis?

Meloxicam is prescription‑only in Australia and is used mainly for symptomatic relief of osteoarthritis and rheumatoid arthritis under TGA registration.

PBS listings generally favour cost‑effective generics where available, which influences dispensing patterns in primary care.

Real‑world PBS data show steady prescribing for chronic musculoskeletal pain, with most clinicians starting at 7.5 mg once daily and increasing to 15 mg if needed.

TGA adverse‑event monitoring mirrors international findings: dyspepsia and elevated liver enzymes are common, while serious GI bleeding and cardiovascular events occur at rates comparable to other non‑selective NSAIDs.

Risk increases with advancing age, multiple comorbidities and polypharmacy.

In perioperative inpatient settings some hospitals use a single 30 mg IV dose as part of multimodal analgesia to reduce short‑term opioid use.

Patients often ask about meloxicam PBS, TGA meloxicam and meloxicam osteoarthritis when discussing access and safety.

Indications And Expanded Uses

Not sure what meloxicam is approved for versus where clinicians use it off‑label?

TGA‑approved indications in Australia principally cover symptomatic relief of osteoarthritis and rheumatoid arthritis in adults.

Paediatric approval varies by formulation and age, so specialist oversight is recommended for children.

Common off‑label uses in Australia include chronic low back pain, tendonitis and single‑dose IV use in perioperative multimodal analgesia.

International labels reference juvenile rheumatoid dosing of 0.125 mg/kg up to a 7.5 mg maximum once daily, but local paediatric use requires specialist involvement.

Use of meloxicam for post‑CABG pain is contraindicated.

Clinicians favour meloxicam where once‑daily dosing and a 20‑hour half‑life improve adherence, but balance this against GI and cardiovascular risk for chronic therapy.

Common search phrases include meloxicam indications, meloxicam off‑label Australia and meloxicam paediatric.

Composition And Brand Landscape

Curious which brands and formulations you might see at the pharmacy?

The active ingredient is meloxicam (INN) and the ATC classification is M01AC06, the oxicam subgroup of NSAIDs.

Mobic is the best‑known innovator brand in many markets, though availability varies and generics are widely supplied in Australia.

Available formulations include oral tablets 7.5 mg and 15 mg, oral suspension 7.5 mg/5 mL and, in some settings, IV vials 30 mg/1 mL.

Local supply chains commonly include Boehringer Ingelheim legacy stock and multiple generic suppliers for retail and hospital supply.

On the PBS patients typically search for terms such as Mobic 7.5 mg or meloxicam tablets when comparing prices.

Australian PBS rules allow generic substitution where therapeutically equivalent generics are listed, and pharmacists often advise cost‑effective options.

Contraindications And Special Precautions

Worried you might be in a high‑risk group for meloxicam harm?

Absolute contraindications include known hypersensitivity to meloxicam or other NSAIDs, history of NSAID‑induced asthma or urticaria, active GI bleeding or perforation, and use for pain after CABG surgery.

Severe hepatic or renal failure is a clear contraindication.

Relative contraindications include established cardiovascular disease or risk factors, anticoagulant therapy, elderly age and past peptic ulcer disease.

Pregnancy should prompt caution; NSAIDs are generally avoided in the third trimester.

Special Australian concerns are higher rates of renal disease among some Indigenous communities and limited follow‑up access in remote areas.

Advise patients that meloxicam can cause dizziness or drowsiness and to take care with driving or machinery.

Dosage Guidelines

Unsure what dose to start or when to reduce meloxicam?

Standard adult dosing for osteoarthritis and rheumatoid arthritis is 7.5–15 mg orally once daily, with most prescribers starting at 7.5 mg.

Elderly patients should start at the lowest effective dose and be monitored closely.

Paediatric dosing referenced in some international labels is 0.125 mg/kg up to a 7.5 mg once‑daily maximum for certain juvenile arthritides; local use requires specialist oversight.

For acute moderate‑to‑severe pain IV meloxicam is given as a single 30 mg adult dose.

Dose reduction or avoidance is recommended for moderate to severe hepatic impairment and severe renal impairment, and it should not be used in patients on haemodialysis.

When used with anticoagulants or in those with prior ulcers, gastroprotection such as a PPI should be considered.

Interactions Overview

Worried about drugs or drinks that increase meloxicam risk?

Meloxicam potentiates bleeding risk with anticoagulants such as warfarin or direct oral anticoagulants and increases GI bleeding when combined with SSRIs.

Concomitant use with ACE inhibitors or ARBs may blunt antihypertensive effects and increase renal risk, especially when combined with diuretics.

Other NSAIDs add cumulative GI and cardiovascular risk and should generally be avoided together.

Alcohol increases the chance of GI irritation and bleeding and patients should be advised to limit intake while taking NSAIDs.

TGA and e‑health reports emphasise polypharmacy in aged‑care as a common contributor to adverse events.

Patients should pause NSAIDs before elective surgery when advised and avoid concurrent systemic corticosteroids unless necessary due to added ulceration risk.

Cultural Perceptions And Patient Habits

Wondering how Australians view mobic and meloxicam for chronic pain?

Patient forums and social media commonly praise the once‑daily convenience and good pain control with meloxicam, but express concern about long‑term safety and cost.

Price‑sensitive consumers ask about PBS coverage and prefer generics for cost savings.

Many patients place trust in pharmacists from chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart for counselling and price comparisons.

Rural and remote patients face access barriers to specialist review and timely monitoring; telehealth prescriptions help but local pathology access may lag.

Indigenous health services stress culturally safe counselling and higher vigilance for renal and cardiovascular comorbidity.

Search trends frequently include meloxicam reviews Australia, meloxicam cost and meloxicam telehealth.

Availability And Pricing Patterns

Want to know where to buy mobic and how much it will cost?

Mobic and meloxicam generics are dispensed nationally through major chains and online pharmacies, though availability of the Mobic brand varies by pharmacy.

PBS listing influences price, with generic meloxicam usually cheaper under PBS subsidy and private purchase costing more.

Telehealth e‑prescribing has increased convenience for patients seeking repeat supplies, but rural customers can face higher courier fees or occasional stock shortages for specific formulations such as suspension or IV packs.

In our online pharmacy, mobic is available without a prescription, with discreet delivery to Australia in 5–14 days.

Typical pack sizes dispensed include tablets in 7.5 mg and 15 mg and oral suspension bottles; storage is at 20–25°C.

Comparable Medicines And Preferences

Trying to choose between meloxicam and other NSAIDs for your patient?

Celecoxib is a COX‑2 selective option that may reduce GI risk but has its own cardiovascular considerations.

Diclofenac is effective but generally carries higher GI and CV risk compared with meloxicam.

Ibuprofen is useful for short‑term acute pain due to a shorter half‑life and flexible dosing.

Piroxicam is another oxicam with a long half‑life but typically higher GI risk.

Choice depends on patient risk profile, PBS availability and cost, comorbidities and patient preference.

Pharmacists often recommend generics for patients prioritising affordability while considering gastroprotection or COX‑2 options for high GI risk patients.

Frequently Asked Questions

1. Can I get meloxicam on the PBS?

   Many meloxicam generics are PBS‑listed; check with your GP or pharmacy for current listings and eligibility.

2. Is meloxicam safe long term?

   Meloxicam can be effective for long‑term use but requires regular review for GI, cardiovascular and renal risks, especially in elderly or comorbid patients.

3. Can I drink alcohol while taking meloxicam?

   Alcohol increases the risk of gastrointestinal bleeding and irritation; limiting or avoiding alcohol while on NSAIDs is advised.

4. What if I miss a dose?

   Take as soon as you remember unless it is near the time for your next dose; do not double up.

Patients are encouraged to report adverse events to the TGA, in line with national guidance on safety monitoring.

Guidelines For Proper Use

Want a quick checklist for counselling a patient starting meloxicam?

Confirm the indication and start dose, usually 7.5 mg once daily for adults, and explain expected onset and that full benefit may take days to weeks for chronic conditions.

Review medical history for heart disease, peptic ulcer, liver or kidney disease and any anticoagulant use.

Advise patients to watch for serious signs such as black stools, severe abdominal pain, sudden breathlessness or a widespread rash and to seek immediate care if these occur.

Recommend gastroprotection with a PPI for those with prior ulcers or when long‑term NSAID therapy is necessary.

Arrange baseline and periodic renal and liver function tests, especially for remote patients where telehealth follow‑up must be tied to local pathology access.

Provide PBS patient information and TGA resources, and if cost is a concern offer generic options and a simple handout on missed‑dose and storage instructions.

Delivery Across Australia